## INDIVIOR PLC (THE 'COMPANY')

## NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS CLOSELY ASSOCIATED WITH THEM

The Company announces that it received notification on July 29, 2024 that Dr. Keith Humphreys, a Non-Executive Director of the Company, acquired 775 Ordinary Shares of US\$0.50 each in the Company ('Shares') at a price of \$12.6741 per share on July 29, 2024.

Following this transaction, Dr. Humphreys has an interest in 2,379 shares in the Company.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr. Keith Humphreys	
2	Reason for the notification		
a)	Position/status	Non-Executive Director / PDMR	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Indivior PLC	
b)	LEI	213800V3NCQTY7IED471	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US\$0.50	
	Identification code	GB00BN4HT335	
b)	Nature of the transaction	Purchase of Shares	
c)	Price(s) and volume(s)	Price(s) \$12.6741	Volume(s) 775
d)	Aggregated information - Aggregated volume - Price	N/A	
e)	Date of the transaction	July 29, 2024	
f)	Place of the transaction	Nasdaq Global Select Market	

4

Þ

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

## DSHWPUQGMUPCGWU